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Abstract
Background
99mTc-mebrofenin hepatobiliary scintigraphy (HBS) was used as a quantitative method to evaluate liver
function. The aim of this study was to compare future remnant liver function assessed by
99mTc-mebrofenin hepatobiliary
scintigraphy with future remnant liver volume in the prediction of liver failure after major liver resection.
Methods Computed tomography (CT) volumetry and
99mTc-mebrofenin hepatobiliary scintigraphy were performed prior to
major resection in 55 high-risk patients, including 30 patients with parenchymal liver disease. Liver volume was expressed
as percentage of total liver volume or as standardized future remnant liver volume. Receiver operating characteristic (ROC)
curve analysis was performed to identify a cutoff value for future remnant liver function in predicting postoperative liver
failure.
Results Postoperative liver failure occurred in nine patients. A liver function cutoff value of 2.69%/min/m
2 was calculated
by ROC curve analysis.
99mTc-mebrofenin hepatobiliary scintigraphy demonstrated better sensitivity, specificity, and
positive and negative predictive value compared to future remnant liver volume. Using
99mTc-mebrofenin hepatobiliary
scintigraphy, one cutoff value suffices in both compromised and noncompromised patients.
Conclusion Preoperative
99mTc-mebrofenin hepatobiliary scintigraphy is a valuable technique to estimate the risk of
postoperative liver failure. Especially in patients with uncertain quality of the liver parenchyma,
99mTc-mebrofenin HBS
proved of more value than CT volumetry.
Keywords Hepatectomy.Liver failure.Liverfunction.
Livervolume.Mebrofenin.CTvolumetry
Introduction
Major liver resection may result in a small postoperative
remnant liver, thereby increasing the risk of postoperative
liver failure, especially in patients with parenchymal disease.
1
Posthepatectomy liver failure is the most frequent cause of
mortality after liver resection. Although the causes of liver
failure are multifactorial, insufficient postoperative remnant
liver function is one of the main contributing factors.
Preoperative computed tomography (CT) volumetry, in
which liver volume is used as an indirect measurement of
liver function, is widely used to identify patients who
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DOI 10.1007/s11605-009-1085-2should be excluded from a planned liver resection or to
select patients who will benefit from preoperative portal
vein embolization (PVE).
1–5 Future remnant liver (FRL)
volume (FRL-V) is expressed as a percentage of total liver
volume (%FRL-V),
3 or as standardized FRL (sFRL), in
which FRL-V is calculated as percentage of total liver
volume based on body surface area (BSA).
4,6 sFRL
recognizes patient characteristics (body weight/BSA) but
has only been validated in patients with healthy livers. In
patients with a normal liver parenchyma, an %FRL-V or
sFRL larger than 25–30% of total preoperative liver volume
is considered sufficient for a safe resection,
3,4,7–9 whereas
in patients with a compromised liver (e.g., fibrosis,
steatosis, or cholestasis), a %FRL-V or sFRL of more than
40% is preferred.
10 The separate cutoff values indicate the
necessity to asses the quality of the liver parenchyma in
order to perform an accurate and safe preoperative risk
analysis using CT volumetry. Preoperative liver biopsy is
currently the most reliable method to assess the quality of
the liver parenchyma. Biopsies are not routinely performed
due the potential unequal distribution of parenchymal
damage
11 and the risk of complications.
12,13 As a result,
the quality of the liver parenchyma frequently remains
unknown, rendering preoperative risk analysis by CT
volumetry less reliable.
For accurate preoperative risk analysis, additional tests
of liver function are required. Dynamic
99mTc-mebrofenin
hepatobiliary scintigraphy (HBS) was developed as a
quantitative method for evaluating total and regional liver
function, including FRL function.
14,15 The hepatic uptake
of
99mTc-mebrofenin is similar to the uptake of organic
anions such as bilirubin.
16 After the hepatic uptake,
99mTc-
mefrofenin is excreted into the bile canaliculi without
undergoing biotransformation during its transport through
the hepatocytes. Although
99mTc-mebrofenin is not metab-
olized, the uptake and intracellular transit are similar to
various endogenous and exogenous substances including
bilirubin, hormones, drugs, and toxins. In a recent publica-
tion, we demonstrated that
99mTc-mebrofenin HBS has
potential to predict postoperative liver failure in a patient
population including both minor and major liver resec-
tions.
17 The advantage of using
99mTc-mebrofenin HBS is
the fact that the same cutoff value can be used for both
patients with a compromised or normal liver parenchyma,
which makes the test applicable in patients with an
uncertain quality of the liver parenchyma. However, it
remains uncertain if
99mTc-mebrofenin HBS is sufficiently
accurate to predict liver failure in a population containing
high-risk patients requiring major hepatic resection. This
study compares preoperative FRL function assessed by
HBS with FRL-V, expressed as %FRL-V and sFRL, in the
prediction of postoperative liver failure after major liver
resection in high-risk patients.
Patients and Methods
Patients
Between May 2000 and November 2006, 213 patients
underwent a partial hepatectomy. Of all patients undergoing
major liver resection (three or more Couinaud segments), both
CT volumetry and HBS were preoperatively performed in 71
patients. Sixteen patients were excluded from the study
because of preoperative PVE (n=15) or partial portal vein
thrombosis (n=1) in the time period between HBS and CT
volumetry. Hence, a group of 55 patients was retrospectively
analyzed with the approval of our Institutional Review Board
with waiver of informed consent. Table 1 summarizes the
types of resection performed. Patients with a preoperative
suspicion of hilar cholangiocarcinoma underwent an
(extended) hemihepatectomy combined with hilar resection
and caudate lobe resection. In cholestatic patients, preoper-
ative biliary drainage was performed more than 6 weeks prior
to surgery using endoscopic retrograde cholangiopancreatog-
raphy or percutaneous transhepatic drainage.
Pre- and perioperative factors associated with postoper-
ative morbidity and mortality were analyzed (Table 5).
Histopathology of the resection specimen was assessed by
an experienced pathologist taking into account features of
cholestasis, steatosis, fibrosis, and chronic inflammation.
Postoperative complications were recorded according to
themodifiedclassificationofsurgicalcomplicationsproposed
by Dindo et al.
18 In-hospital complications were recorded as
well as complications requiring hospital readmission within
3 months related to the operation. Minor complications
included grade 1 and grade 2 complications. Major
complications were defined as grade 3 and severe compli-
procedure Number of patients Percentage Weight resection specimen (g)
Extended right hemihepatectomy 14 25.5 975±247
Right hemihepatectomy 26 47.2 936±396
Extended left hemihepatectomy 1 1.8 443
Left hemihepatectomy 14 25.5 348±120
Total 55 100.0
Table 1 Types of Liver Resec-
tion with the Corresponding
Weight of the Resection
Specimen
370 J Gastrointest Surg (2010) 14:369–378cations as grade 4 and grade 5 complications. Liver failure
was defined as bilirubin plasma levels >50 µmol/l and/or
prothrombin time index <50%,
19 elevated plasma ammonia
levels combined with signs of hepatic encephalopathy and/or
hepatorenal syndrome, requiring intensive care treatment.
Surgical Technique
Surgery was performed under low central venous pressure
(<4 cm H2O). Liver parenchymal transsection was per-
formed using Cavitron Ultrasonic Surgical Aspirator (Valley
Lab, Boulder, CO, USA). Pringle maneuver was applied in
29 patients (54%) to reduce intraoperative blood loss, with a
mean ischemic period of 37±13 min. Intermittent clamping
was applied in eight patients (15%).
Scintigraphic Imaging and Data Acquisition
HBS was performed using
99mTc-mebrofenin as previously
described.
14,15 Briefly, after injection of 85 MBq of
99mTc-
mebrofenin (Bridatec; GE-Amersham Health), dynamic
images were obtained with a γ-camera (Diacam, Siemens,
Milwaukee, WI, USA) for 60 min. During the first 10 min,
60 frames of 10 s were acquired (liver uptake phase)
followed by 50 frames of 1 min (liver excretion phase).
Total hepatic
99mTc-mebrofenin uptake rate was calculated as
described by Ekman et al.
20 On preoperative HBS, regions
of interest (ROIs) were drawn around the total liver, the heart
(serving as blood pool), and the total field of view. From
these ROIs, three time–activity curves were generated
(Fig. 1). Total hepatic
99mTc-mebrofenin uptake rate, repre-
senting total liver function (TL-F), was calculated as percent
per minute: (%/min) (of the injected dose) based on these
three parameters. Calculations of hepatic
99mTc-mebrofenin
uptake rate were performed using measured values obtained
between 150 and 350 s postinjection to ensure that hepatic
uptake calculations were performed during a phase of
homogenous distribution of the agent in the blood pool,
before occurrence of the rapid phase of hepatic excretion. To
compensate for differences in individual metabolic require-
ments, TL-F was divided by BSA and expressed as percent
per minute per square meter: (%/min/m
2). For determination
of FRL uptake, a ROI was drawn around the FRL by two
independent investigators, blinded for the results, according
to the performed resection, and interobserver variation was
calculated. The round ligament was used as the border
between segment three and four. Cantlie’s line, projected on
the liver surface as a plane between the middle of the
gallbladder fossa (visible in the late phase of the scintigra-
phy) and the inferior caval vein, was used as a border
between the right and left liver lobes. In addition, the anterior
projection of the liver on the CT volumetry was used as a
guideline for delineating the FRL on the HBS images
(Fig. 1). FRL uptake function (FRL-F) was calculated by
dividing counts within the delineated FRL by the total liver
counts and multiplying this factor with total liver
99mTc-
mebrofenin uptake (TL-F) and expressed as percent per
minute per square meter: (%/min/m
2). In 33 patients, a
postoperative HBS was performed within 3 days after the
operation to measure actual remnant liver function.
CT Volumetry
Contrast-enhanced CT scans were generated with a helical
scanner (Philips, Eindhoven, The Netherlands). Manual 3D
reconstructions of the liver were made using reconstructed
5-mm-thick axial slices from 2–3-mm original slices. The
total liver as well as tumor(s) and the FRL were manually
outlined using portal and hepatic veins as landmarks for
segmental division. Integrated software (Mx-View 3.52,
Philips Medical Systems) was used to calculate total liver
volume (TL-V), tumor volume (TV), and FRL-V. All
delineations were made by an experienced radiologist.
FRL-V was expressed as percentage of TL-V using the
formula:
%FRL   V ¼
FRL   V
TLV   TV ðÞ
  100%
The nontumorous total liver volume (
NTTL-V) was
calculated by excluding the tumor volume from the TL-V.
Standardized FRL Measurements
FRL-V was determined using CT volumetry, while total
liver volume (
calTL-V) was calculated using a formula
based on BSA
6: calTL   V ¼  794:41 þ 1;267:28   BSA
BSA ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
height cm ðÞ   weight
p
kg ðÞ =3;600
  
.
The sFRL was calculated as the percentage between
FRL-V and calculated TL-V.
Preoperative Risk Assessment
Receiver operator characteristics (ROC) curve analysis was
used to calculate the optimal cutoff value for FRL-F in
predicting postoperative liver failure. Cutoff values were
determined based on the following assumptions: Firstly, the
chance that liver failure would develop while the test result
was above the cutoff value needed to be as low as possible.
Secondly, a test result below the cutoff value should
accurately select high-risk patient who might benefit from
PVE. Based on literature, cutoff values for %FRL-V and
sFRL were set at 30% for patients with normal liver
parenchyma
9 and 40% for patients with a compromised
liver.
10 Positive predictive values (PPV), negative predic-
tive values (NPV), as well as sensitivity and specificity
were determined for each method.
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Statistical analysis was performed with GraphPad Prism
(GraphPad Software, San Diego, CA, USA) and Statistical
Package for Social Sciences (SPSS 12.02, Chicago, IL,
USA). ROCcurve analysiswasusedtoidentifyacutoff value
for FRL-F in predicting postoperative liver failure. Univariate
analysis of preoperative and intraoperative variables was
performed by the independent t test for continuous parame-
ters and by Pearson’s
2tests and Fisher’s exact test for
categorical data. Correlation between variables was tested
using the Pearson correlation coefficient r.C o n t i n u o u sd a t a
were compared by independent sample t test and expressed
as mean±standard deviation. All statistical tests were two-
tailed, and differences were considered significant at a P
value of ≤0.05.
Results
Patient Characteristics
CT volumetry and
99mTc-mebrofenin HBS were performed
in 55 patients (male 26, female 29, mean age 59±13 years).
Indications for liver resection are shown in Table 2. Thirty
patientswerediagnosedwithacompromisedliverparenchyma
based on the histopathological evaluation of the resection
specimen by an experienced pathologist, including cirrhosis
(n=2), severe fibrosis (n=3), steatosis (>30% of the hepato-
cytes affected; n=3), severe cholestasis (n=8), chronic inflam-
mation (n=3), or a combination of these diseases (n=11).
Liver Function and Liver Volume
TL-F was significantly lower in patients with parenchymal
liver disease (7.4±1.4%/min/m
2) as compared to patients with
healthy liver parenchyma (8.5±1.7%/min/m
2, P=0.007).
NTTL-V was significantly larger in patients with compro-
mised livers (1,037.1±208.0 vs. 877.0±143.3 mL/m
2, P=
0.001; Fig. 2).
Figure 1 An example is shown
of summed HBS images from
150–300 s after i.v. injection of
99mTc-mebrofenin (a). A ROI is
drawn around the entire liver
(red line) and around the medi-
astinum (blood pool; yellow
line). A third ROI is drawn
around the future remnant liver
(green line). A blood pool cor-
rected liver-uptake time–activity
curve is shown in b. The hepatic
99mTc-mebrofenin uptake is
calculated as an increase of
99mTc-mebrofenin uptake (y-
axis) per minute over a time
period of 200 s (x-axis). c The
use of the anterior projection of
the liver on the CT volumetry
image as a guideline for
delineating the FRL on the HBS
image (d).
Table 2 Indications for Liver Resection
Liver metastasis (n=14)
Hilar cholangiocarcinoma (n=19)
Intrahepatic cholangiocarcinoma (n=3)
Hepatocellular carcinoma (n=6)
Benign biliary strictures (n=7)
Benign lesions (n=6)
372 J Gastrointest Surg (2010) 14:369–378According to the type of resection performed, FRL-F was
calculated for each individual patient by two independent
observers.Theinterobserveragreementwasexcellent(Pearson
r=0.97), and Bland–Altman analysis revealed almost no bias
between the two observers (mean bias of 0.00058 with 95%
limit of agreement between −0.835 and 0.836). Preoperative
FRL-F correlated strongly with actual postoperative remnant
liver function determined within 3 days after surgery (Pearson
r=0.83, P<0.0001; Fig. 3). Liver weight of the resection
specimen revealed a strong correlation (Pearson r=0.91, P<
0.0001) with its volume assessed by CT volumetry, confirm-
ing the CT measurements.
FRL-V correlated well with FRL-F (Pearson r=0.72, P=
0.0001) in patients with normal livers. In contrast, patients
with a compromised liver demonstrated only a moderate
correlation between FRL-Vand FRL-F (Pearson r=0.61,P<
0.0003). The slope coefficient of the linear regression curve
indicated that FRL-V is associated with significantly (P=
0.0015, analysis of covariance test) reduced FRL-F in
compromised livers as compared to normal livers (Fig. 4).
Postoperative Complications
In 42 of the 55 (76%) patients, one or more complications
occurredfollowingliver resection(Table3). Minor and major
complications were evident in 14 patients (25%) and 13
patients (24%), respectively. Fifteen patients (27%) devel-
oped severe complications requiring ICU treatment, and the
mortality rate was 15%. Patients with severe complications
had significantly lower FRL-F as compared to patients with
no complications (P=0.0043), minor complications (P=
0.0028), or major complications (P=0.0046)
Nine patients (16%) developed postoperative liver failure,
of which eight patients died. In four patients, liver failure was
evident within 1 week after the operation. Five patients
developedliver failure within several weeks after the operation
in conjunction with signs of sepsis. Evidence of a compro-
mised liver was seen in eight patients (89%), and in seven
patients, an extended hemihepatectomy had been performed.
The FRL-F was significantly lower in patients with postoper-
ative liver failure (2.18% vs. 4.32%/min/m
2, P=0.0001).
Preoperative and Intraoperative Parameters Associated
with Liver Failure
Univariate analysis revealed that elderly patients (P=0.043),
small %FRL-V (P=0.024), small sFRL (P=0.012), small
Figure 4 Scatter plot showing the correlation between FRL-F and
FRL-V. In patients with normal livers (black line), FRL-V correlated
well with FRL-F (Pearson r=0.71, P=0.0001). Patients with compro-
mised livers (gray line) showed a moderate correlation between FRL
volume and FRL function (Pearson r=0.61, P<0.0003).
Figure 3 Scatter plot showing the correlation between preoperative
FRL-F and actual postoperative remnant liver function measured
within 3 days after surgery (33 patients, Pearson r=0.81, P<0.0001).
Figure 2 Total hepatic
99mTc-mebrofenin uptake according to
parenchymal status. Patients with parenchymal liver disease had
significantly less liver (uptake) function (gray box, 7.4±1.4%/min/m
2)
as compared to patients with healthy liver parenchyma (white box,8 . 5±
1.7%/min/m
2, P=0.007; a). Total liver volume: (
NTTL-V) was
significantly higher in patients with compromised livers (1,037.1±
208.0 vs. 877.0±143.3 mL/m
2, P=0.001; b).
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operating time (P=0.0018), increased blood loss (P=
0.0018) during the operation, and the presence of a
compromised liver parenchyma (P=0.024)weresignificantly
associated with postoperative liver failure (Table 4). Due to a
small sample size in the liver failure group (n=9), no
multivariate analysis was performed.
Preoperative Prediction of Postoperative Liver Failure
ROC analysis revealed that a cutoff value for FRL-F of
2.69%/min/m
2 was able to identify patients who developed
postoperative liver failure with a sensitivity of 89% and a
specificity of 87% (Fig. 5). The risk of postoperative liver
failure in patients with a FRL-F above 2.69%/min/m
2 was
2.4% (with a NPV of 97.6% and a likelihood ratio for a
negative test result of 0.12). The PPV was 57.1% with a
likelihood ratio for a positive test result of 6.8. Table 5
summarizes the sensitivity, specificity, PPV, NPV, and
likelihood ratios of the different tests. For an accurate use
of %FRL-V and sFRL, two cutoff values were used, and
patients were divided in patients with a normal liver
parenchyma and patients with a compromised liver paren-
chyma based on the histopathology ofthe resection specimen.
Using
99mTc-mebrofenin HBS, one cutoff value sufficed in
both compromised and noncompromised patients. Assuming
that, of all the patients, the quality of the liver parenchyma
was preoperatively known, sensitivity, specificity, and
positive and negative predictive values were still better for
FRL-F compared to %FRL-V and sFRL (Table 5).
Discussion
Accurate measurement of liver function before liver
resection is crucial in the assessment of resectability,
especially in patients requiring major liver resection. The
availability of preoperative PVE to induce hypertrophy of
the FRL has further increased the importance of preoper-
ative assessment of regional hepatic function.
7,21–24 In the
present study, dynamic planar
99mTc-mebrofenin HBS was
used to measure liver function. This technique can be
implemented in every hospital with a nuclear medicine
department, is easy to perform, and has a small interob-
server variability. More importantly, preoperative estimated
function of the future remnant liver (FRL-F) correlates
strongly with actual postoperative liver function,
14 indicat-
ing that dynamic planar
99mTc-mebrofenin HBS is an
accurate method to assess FRL-F.
In this study, we compared FRL-F measured by
99mTc-
mebrofenin HBS with two parameters based on CT
volumetry, which are widely accepted parameters to
determine the possible extent of resection.
1–5 Patients with
a compromised liver had a significantly lower liver function
compared to patients with normal liver parenchyma,
whereas their liver volume was significantly larger. FRL-
V showed a strong relation with FRL-F in patients with
normal liver parenchyma. In contrast, FRL-V and FRL-F
only moderately correlated in patients with compromised
liver parenchyma in whom FRL-V was associated with
reduced FRL-F. The impact of different parenchymal
diseases such as steatosis, cholestasis, and fibrosis on liver
function and liver volume is unknown and may vary among
individuals. In addition, parenchymal damage is often not
equally distributed,
11 which can partially explain the
moderate correlation between FRL-Vand FRL-F in patients
with compromised livers. ROC curve analysis yielded an
FRL-F cutoff of 2.69%/min/m
2 for the prediction of
postoperative liver failure. This cutoff value is comparable
to the cutoff value determined in a patient population
including both minor and major resections.
17
A reliable preoperative test should primarily establish
whether patients with a FRL-F above the critical threshold
Figure 5 Receiver operator characteristic curve analysis of FRL-F in
the prediction of liver failure. A cutoff value for FRL-F of 2.69%/min/
m
2 identified patients with a significant risk of developing postoper-
ative liver failure (area under the curve=0.916; 95% confidence
interval 0.837–0.994).
Table 3 Postoperative Complications
Grade 0 (n=13) No complications
Grade 1* (n=5) Minor complications
Grade 2* (n=9) Minor complications
Grade 3a (n=12) Major complications
Grade 3b (n=1) Major complications
Grade 4a (n=5) Severe complications
Grade 4b (n=2) Severe complications
Grade 5 (n=8) Severe complications
Grade 1 needed no therapy except analgetics, diuretics, anti-emetics, and
physiotherapy.Grade2complicationsrequiredpharmacologicaltreatment.
Grade 3 complications required surgical, endoscopic, or radiological
intervention (grade 3a under local anesthetics, grade 3b under general
anesthetics). Grade 4 complications included life-threatening complica-
tions requiring ICU management (grade 4a with single organ dysfunction,
grade 4bwithmulti-organfailure).Grade 5complicationsresultedindeath
*One patient could have multiple grade 1 or 2 complications
374 J Gastrointest Surg (2010) 14:369–378can be safely resected. One patient developed liver failure
despite a FRL-F above 2.69%/min/m
2 (Table 6). This
cirrhotic patient developed massive necrosis after left
hemihepatectomy, due to an obliterated right hepatic artery
and a compromised portal venous system. When CT
volumetry would have been used as selection criterion for
operation, two patients developed liver failure despite a %
FRL-V of more than 40% (Table 6). Standardized FRL
wrongly predicted a safe resection in three patients
(Table 6). Although the formula generally used to calculate
TL-V based on BSA is used for all patients, it is derived
from patients with normal liver parenchyma. In our study,
patients with a compromised liver had significantly larger
liver volumes resulting in a relatively larger FRL-V in
relation to their BSA. As a consequence, there is an
overestimation of liver function in these patients.
Secondly, a preoperative test should be accurate in
selecting high-risk patients who might benefit from PVE,
without treating patients unnecessarily. Despite having a
FRL-F below the critical value of 2.69%/min/m
2, 43% of
these high-risk patients did not develop liver failure. In
literature, a similar percentage was reported when using CT
volumetry for the prediction of postoperative hepatic
dysfunction.
8 Additional negative predictive factors, in-
Table 4 Comparison of Pre- and Intraoperative Parameters in Patients with or Without Liver Failure
Patients with liver failure (n=9) Patients without liver failure (n=46) P value
Demographics
Male/female 7:2 19:27 0.069
a
Age 67.1±6.0 (58–67) 57.1±13.7 (18–78) 0.027
b
BMI 25.1±2.1 24.0±3.6 0.33
b
FRL volume
%FRL-V (%) 35.0±22.0 49.7%±17.8 0.013
b
sFRL (%) 35.2±9.2 49.2%±3.6 0.018
b
FRL-F (%/min/m
2) 2.2±0.6 4.3%±1.6 0.001
b
Comorbidity
Diabetes (yes/no) 2:7 5:41 0.32
a
Chronic hepatitis (yes/no) 2:7 3:43 0.18
a
Vascular disease(yes/no) 3:6 9:37 0.39
a
Compromised liver (yes/no) 8:1 22:24 0.024
a
Resection type
Left hemihepatectomy 1 13
Right hemihepatectomy 1 25 0.001
c
Extended hemihepatectomy 7 8
Preoperative laboratory values
AST 51.4±19.1 48.2±32.4 0.24
b
ALT 57.9±27.2 65.6±65.6 0.55
b
Bilirubin 19.9±14.9 14.2±12.0 0.20
b
AF 265.2±204.6 280.1±260.5 0.76
b
GGT 409.9±272.7 392.7±605.7 0.13
b
Albumin 39.4±5.8 39.5±5.9 0.84
b
Prothrombin time 13.0±1.5 13.1±0.90 0.63
b
Intraoperative parameters
Blood loss (mL) 5,200 cc±2,673 3,025±2,464 0.021
b
Operating time (min) 507.4±135.1 382.3±131 0.011
b
Pringle maneuver yes/intermittent/no 3:2:3 26:6:14 0.62
c
Pringle time (min) 35.0±5.0 36.71±13.5 0.96
b
Intermittent total ischemia time (min) 40.0 47.6 0.5
b
AST aspartate aminotransferase, ALT alanine aminotransferase, AF alkaline phosphatase, GGT gamma-glutamyltransferase, BMI body mass index
aFisher’s exact test
bMann–Whitney U test
cχ
2 test
J Gastrointest Surg (2010) 14:369–378 375cluding high body mass index, significant intraoperative
blood loss, and prolonged operating time, were described in
patients with hepatic dysfunction, underlining the multifac-
torial cause of postoperative liver failure. In our study,
univariate analysis revealed that, besides small FRL volume
and function, increased intraoperative blood loss, prolonged
operating time, a compromised liver parenchyma and older
age were associated with liver failure. Unfortunately, a
multivariate analysis was not possible in our study due to
the small number of patients with postoperative liver
failure. Cutoff values for the prediction of postoperative
complications and hepatic dysfunction have been reported
using CT volumetry,
3,4,7–9 indocyanine green clearance
test,
25 galactose elimination capacity,
26 and
99mTc-GSA
scintigraphy.
27–30 These cutoff values were, however,
mostly not based on accurate risk calculations and no or
inappropriate multivariate analyses had been performed.
Morbidity and mortality rates reported in our study were
high, which is explained by the patients selected for this
study. We only included patients undergoing major liver
resection of which the majority (55%) had parenchymal
liver disease. A relatively high proportion (39%) of patients
had undergone resection on the suspicion of hilar chol-
angiocarcinoma, including six patients who had developed
postoperative liver failure. These patients require large
resections and biliary anastomoses, with increased risk of
postoperative morbidity and mortality, reported up to 10–
20%.
31–33 The overall postoperative mortality in patients
operated for benign lesions or liver metastasis in our
institution is 2%.
34 In addition, none of the patients included
in this study had undergone PVE. In some patients who
developedpostoperativeliverfailure,PVEwouldbeindicated
in retrospect; however, in these patients, the performed
resection was larger than anticipated because of unexpected
intraoperative findings. Patients included in this study may be
different from patient populations in other clinical practices in
which most patients have noncompromised livers. However,
the fact that postoperative morbidity and mortality were
considerable did add necessary power to the study in which
risk assessment was the primary goal. Further research is,
however, warranted for subgroup analysis of different patient
populations.
The main advantage of HBS lies in the fact that liver
function is measured, taking into account the presence of
underlying parenchymal liver disease. Hence, one cutoff
value for the prediction of liver failure suffices in all
possible patients regardless of the quality of the liver
parenchyma. In contrast, volumetric assessment of the FRL
Liver parenchyma FRL-F (%/min/m
2) %FRL-V (%) sFRL (%)
1 Normal 2.17 46 57
2 Compromised 2.52 38 24
3 Compromised 2.67 22 38
4 Compromised 1.56 20 23
5 Compromised 2.22 32 31
6 Compromised 1.41 29 41
7 Compromised 2.17 24 25
8 Compromised 1.51 16 19
9 Compromised 3.36 88 101
Table 6 Overview of the
Results of the Three Different
Preoperative Tests in Patients
with Liver Failure
The marked values indicate a
false negative result of the test
Table 5 Overview of the Sensitivity, Specificity, PPV, NPV as well as likelihood ratio’s for FRL-F, %FRL-V, and sFRL in the Prediction of
Postoperative Liver Failure
Outcome parameter FRL-F %FRL-V sFRL
Cutoff value 2.69%/min/m
2 Normal liver <30% Normal liver <30%
Compromised liver <40% Compromised liver <40%
Sensitivity 89% 78% 67%
Specificity 87% 80% 87%
PPV 57% 44% 50%
NPV 98% 95% 93%
LR+ 6.8 4.0 5.1
LR− 0.12 0.19 0.38
FRL future remnant liver, %FRL-V future remnant liver/total liver volume percentage, PPV positive predictive value, NPV negative predictive
value, LR+ likelihood ratio for positive test result, LR− likelihood ratio for negative test result
376 J Gastrointest Surg (2010) 14:369–378requires two distinct cutoff values for patients with a
compromised or noncompromised liver, assuming that the
quality of the liver parenchyma is known. Especially in
patients with uncertain quality of liver parenchyma,
preoperative HBS is therefore of more value than %FRL-
Vor sFRL. The results of our study have led us to use HBS
routinely, in addition to CT volumetry, in all patients
considered for major liver resection. Preoperative PVE is
performed when FRL-F is lower than 2.69%/min/m
2 or %
FRL-V is less than 30%. Although around 40% of these
patients will not develop liver failure, the risk of a
potentially lethal complication outweighs the relatively
low complication rate observed after PVE.
35
Conclusion
HBS is a simple technique that can be implemented in
every hospital with a nuclear medicine department. It is a
valuable technique to estimate the risk of postoperative
liver failure in high-risk patients undergoing major liver
resection. Especially in patients with uncertain quality of
the liver parenchyma,
99mTc-mebrofenin HBS is of more
value than CT volumetry since only one cutoff value can be
used in both normal and compromised livers. Therefore,
additional HBS can improve risk assessment in patients
requiring extensive liver resection.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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